Rescriptor
Rescriptor Uses, Dosage, Side Effects, Food Interaction and all others data.
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Rescriptor is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Rescriptor binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Rescriptor does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Rescriptor.
| Trade Name | Rescriptor |
| Availability | Discontinued |
| Generic | Delavirdine |
| Delavirdine Other Names | Delavirdin, Delavirdina, Delavirdine, Delavirdinum |
| Related Drugs | Biktarvy, Truvada, tenofovir, ritonavir, Complera, Atripla, Stribild |
| Type | Oral |
| Formula | C22H28N6O3S |
| Weight | Average: 456.561 Monoisotopic: 456.194359482 |
| Protein binding | 98% |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Canada, United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Rescriptor is a non-nucleoside reverse transcriptase inhibitor used to treat HIV infection.
For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
Rescriptor is also used to associated treatment for these conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
How Rescriptor works
Rescriptor binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Toxicity
Major toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.
Food Interaction
- Take with or without food. The absorption is unaffected by food.
Rescriptor Drug Interaction
Moderate: esomeprazole, esomeprazole, ritonavir, ritonavirUnknown: lactobacillus acidophilus, lactobacillus acidophilus, nitazoxanide, nitazoxanide, dicyclomine, dicyclomine, lamivudine, lamivudine, crofelemer, crofelemer, enfuvirtide, enfuvirtide, raltegravir, raltegravir, atropine / diphenoxylate, atropine / diphenoxylate
Rescriptor Disease Interaction
Elimination Route
Rapidly absorbed
Half Life
5.8 hours
Elimination Route
Rescriptor is extensively converted to several inactive metabolites by cytochrome P450 3A (CYP3A). Rescriptor was excreted in the milk of lactating rats at a concentration three to five times that of rat plasma.
Innovators Monograph
You find simplified version here Rescriptor
